Background: A pathophysiological link exists between dysregulation of MEF2C transcription factors and heart failure (HF), but the underlying mechanisms remain elusive. Alternative splicing of MEF2C exons a, b and g provides transcript diversity with gene activation or repression functionalities.
Introduction
Heart failure (HF) is a prevalent and morbid illness caused by many common diseases such as ischaemic heart disease, hypertension and diabetes. Typically, the onset of HF is gradual and arises from the progressive adverse remodelling of the cardiac chambers and the decline in pumping function [1] . Although many potentially unfavourable alterations may contribute to the remodelling process and progression to HF, the dropout of cardiomyocytes, related either to their degeneration or death, is a central component to the performance declining in failing hearts [2, 3] . Both degeneration and death are outcomes of the pathological responses of cardiomyocytes to long-term exposure to neurohormonal and mechanical stressors that occur in the settings of the HF predisposing diseases and risk factors [4] . The cellular processes leading to these events denote an extensive transcriptional reprogramming of cardiac gene expression, which results in altered expression of genes encoding components of the sarcomere, cytoskeleton, calcium handling, ion transport and energy metabolism [5] . Preclinical and clinical studies have defined a small set of transcription factors (e.g. MEF2 and NFAT) that are drivers of the unfavourable transcriptional reprogramming and the maladaptive remodelling in failing hearts [5, 6] . It remains unclear, however, how the dysregulation of transcription factors contributes to the dropout of cardiomyocytes in failing hearts.
Research in cardiac models has provided evidence for essential roles of the Myocyte Enhancer Factor 2 (MEF2) family of transcriptional regulators (encoded by four genes: Mef2a, -b, -c, and -d) in the pathological cardiac remodelling and failure. Forced expression of MEF2A, MEF2C or MEF2D in the postnatal mouse heart translates into pathological remodelling, featured, with some differences of detail, by dilated cardiomyopathy with little or no hypertrophy [7À9]. In contrast, inhibition of MEF2 signalling by a dominant-negative MEF2 mutant protein in the mouse adult heart attenuates the development of cardiomyopathy triggered by the calcineurin activation [7] . Moreover, depletion of Mef2c by siRNA attenuates both the hypertrophic cardiac growth and the upregulation of Natriuretic Peptide A (NPPA) in response to pressure overload [10] . Consistent with the observations in mouse models, human genetic studies have shown alterations in the expression of genes regulated by MEF2 in patients in the end stage of HF [11] . Furthermore, increased expression of MEF2C in the left ventricle has been reported as a hallmark of human HF [12] . Less is known, however, regarding the molecular and cellular processes underlying the deleterious influence of MEF2 in the heart.
Regulation of the MEF2 function is reported to occur by various means, including the control of MEF2 protein abundance, post-translational modifications and association with other transcription factors and co-regulators [13] . Also, Mef2 genes use alternative splicing to encode transcripts with three possible differentially regulated spliced exons [14, 15] . At least eight different splice variants of MEF2C are predicted, according to the composition of the alternative expression of the exon 3 (either a1 or a2), the inclusion/exclusion of the b domain and the inclusion/exclusion of the g fragment from the last coding exon [15] . The mutually exclusive splicing exons a1 and a2, which encode the 3 0 region adjacent to the MADS/MEF2 DNA binding domain, has been reported to be directly regulated by the splicing factor Rbfox1 [16] . Notably, Rbfox1 repression correlates to an enhanced a1/a2 ratio and the development of cardiac hypertrophy and HF in the mouse. The b exon encodes a domain that contains multiple acidic residues in the cognate proteins. The insertion of this domain in the MEF2 protein substantially enhances the activity of the transactivation domain; however, only the transcripts expressed in the brain and in skeletal muscles seem to contain this domain [15] . The domain encoded by the last coding exon of MEF2 genes is fully included in all MEF2A and MEF2D variants. However, in the transcripts of MEF2C, an alternative splicing process may yield the inclusion or exclusion of the g fragment (32 amino acid residues) of the last domain. Intriguingly, the inclusion of the g fragment in the MEF2C transcripts entails a transrepressor functionality that is dependent on the phosphorylation of the Ser396 residue within this fragment in the cognate protein [15] . Mef2c is expressed predominantly as gÀ isoforms in the healthy mouse heart [14] ; however, the implications of the g fragment inclusion in the MEF2C for the homeostasis of the heart remain unexplored.
In this study, we have characterized the biological role and potential clinical relevance of the MEF2Cg+ transrepressor variant in the pathogenesis of HF. Specifically, we demonstrate that the levels of MEF2Cg+ are increased in the failing mouse and human hearts. Our results highlight that upregulation of MEF2Cg+ promotes an extensive transcriptional reprogramming accompanied by a partial cell cycle re-entry, dedifferentiation and apoptosis of cardiomyocytes, thereby contributing to the adverse remodelling of the failing hearts. These results provide a new understanding of MEF2C implications for HF, where MEF2Cg+ upregulation causes a previously unappreciated transcriptional reprogramming associated with pathological cardiac remodelling.
Materials and methods

Animals
Primary cultures of neonatal (NRVMs) and adult rat ventricular myocytes (ARVMs) were obtained from 1 to 2 day-old and 6 to 8 week-old Wistar rats, respectively. Male mice 10À12 week-old were used to generate myocardial infarction through left coronary artery ligation. We purchased the transgenic mice FVB-Tg(Myh6-Mef2c) from The Jackson Laboratory (Bar harbor Maine, USA), stock number 010586. The MEF2Cgtransgenic mice were generated by the Model Organism Laboratory at LNBio/CNPEM, as detailed in the Supplementary Material. The transgenic mice used in this study were males
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Evidence before this study Heart failure (HF) remains a significant cause of disability and mortality worldwide. At the cellular level, HF correlates to pathological changes in cardiomyocytes driven by dysregulated signal transduction cascades, which in turn alters downstream transcriptional programs. Previous studies indicate an essential role of the Myocyte Enhancer Factor 2C (MEF2C) transcriptional regulator in the HF, but the underlying mechanisms were unclear. Interestingly, alternative splicing of MEF2C exons a, b and g provides transcript diversity with gene activation or repression functionalities, imposed by the alternative expression of the g exon. In this study, we explored the hypothesis that the selective expression of the transrepressor MEF2Cg+ variant may be a critical determinant of the detrimental cardiac effects of MEF2C.
Added value of this study
We identified the transrepressor variant MEF2Cg+ as a detrimental factor or mediator in HF. Our findings show that MEF2Cg+ is significantly upregulated in human and murine failing hearts. Overexpression of MEF2Cg+ either in cardiomyocytes or in cardiac-specific transgenic mice induces an overall downregulation of genes related to sarcomere, cytoskeleton and energy metabolism, while genes related to cell cycle were upregulated. Accordingly, differentiated cardiomyocytes overexpressing the transrepressor MEF2Cg+ re-entered into the cell cycle but did not execute cytokinesis. These events culminate in multinucleation and apoptosis, accelerating the vicious cycle in the pathophysiology of HF.
Implications of all the available evidence
We suggest that enhanced expression of MEF2Cg+ is maladaptive and maybe a critical factor in the pathogenesis of HF. In this regard, inhibiting the splicing reactions that favour the appearance of the repressor variant of MEF2C might potentially constitute a new therapeutic modality to interfering in the progression of HF. aged 4 to 6 months. All animals were handled in compliance with the principles of laboratory animal care formulated by the Animal Care and Use Committee of the State University of Campinas protocol number 3095-1 and Animal Care and Use Committee CEUA/CNPEM protocol number 12 and 31.
Human studies
The study has been carried out following the Declaration of Helsinki (2000) of the World Medical Association and has been approved by the Pontifical Catholic University of Campinas, Institutional Ethics Committee. All patients gave informed consent.
Patient selection
Patients with myocardial infarction, left ventricle (LV) dysfunction and with akinetic wall region determined by cardiac magnetic resonance imaging (MRI) were selected for LV reconstruction and revascularization. The decision regarding revascularization was based on clinical grounds (symptoms, presence/absence of ischemia/viability, and angiographic findings) [17] .
Operative procedure
With the patient supported by cardiopulmonary bypass, myocardial protection was achieved with antegrade and retrograde blood cardioplegia. The ventricular restoration was performed using the technique described previously as endoventricular reconstruction [18] .
Tissue sampling
Endomyocardial biopsy samples were taken from the LV remote area previously selected according to cardiac MRI. The samples were immediately frozen in liquid nitrogen and stored at À80°C.
Quantification of mRNAs
The total RNA from cardiac or cell samples was isolated using Trizol Ò according to the manufacturer's instructions. For mRNA quantification, target genes expression was analysed by SYBR Green qPCR (with Dissociation Curve) program on the Mx3000TM Comparative Quantitative PCR System (Stratagene). The oligonucleotides used in this study were listed in Supplementary Table 1 . All reactions were performed with reference dye normalisation. The median cycle threshold value was used for analysis, and all cycle threshold values were normalised to the GAPDH mRNA expression level.
Total RNA from human hearts
The amounts of the MEF2C transcripts in the samples of the left ventricle of patients with myocardial infarction were compared with those in commercially available total RNA from Normal Human Heart Left Ventricle (BioChain Institute Incorporated, Newark, CA, catalog number: R1234138-50), as described by the manufacturer.
Confocal microscopy
Fixed tissue sections and cells were blocked with 1% BSA, 0.1% Triton-X, 50 nM Glycine in 0.1 M PBS on ice. The samples were incubated with phospho-histone H3 ser10 À pH3 antibody (06À570, Millipore) overnight at 4°C. Alexa Fluor-488-conjugated goat anti-rabbit (1:200) or Alexa Fluor-568-conjugated goat antimouse (1:200) secondary antibodies were used at room temperature. Alternatively, samples were incubated with rhodamine-conjugated phalloidin (1:50; Molecular Probes) at room temperature for two h. The slides were then mounted with VectaShield with DAPI. Samples were examined using a Leica TCS SP8 confocal on a Leica DMI 6000.
Transmission electron microscopy
For cell samples, the culture medium was replaced by a fixative solution consisting of 2.5% glutaraldehyde, sodium cacodylate buffer (0.1 M) at pH 7.4 and CaCl 2 (3 mM) for 5 min at room temperature and additional 1 h on ice. The cells were then rinsed with cacodylate buffer/CaCl 2 and were post-fixed in 1% OsO 4 , cacodylate buffer (0.1 M), CaCl 2 (3 mM), and potassium ferrocyanide solution (0,8%) for 30 min on ice. Next, the cells were washed with Milli-Q water and stained with uranyl acetate (2%) overnight at 4°C. The cells were then washed in milli-Q water and dehydrated in an ethanol gradient. Then, adherent cells were embedded in Epon 812 resin. Resin polymerization was controlled in an incubator (60°C) for 72 h. Monolayer culture ultra-thin sections were stained with uranyl acetate and lead citrate. For heart samples, small pieces were fixed in 2.5% glutaraldehyde (Electron Microscope Science, Hatfield, PA, USA) in 0.1 M cacodylate buffer containing 0.3% tannic acid for 4 h at 4°C. After, the tissues were post-fixed with 1% osmium in 0.1 M cacodylate buffer for 1 h and then dehydrated through a graded series of acetone and embedded in Epon (EMbed-812; Electron Microscopy Sciences, Hatfield, PA). Ultrathin sections were stained with uranyl acetate and lead citrate. The sections were examined using an LEO 906 (Zeiss) electron microscope operated at 60 kV. For the quantification of the fragmented sarcomeres, digital electron microscopy pictures of each group of the study were taken randomly at a magnification of 12,930x and 16,700x. A total of 20 fields of view per group were used to analyze more than 300 sarcomeres. The percentage of fragmented sarcomere was annotated.
Data sharing
The microarray data files (Affymetrix CEL files) for all the experiments described here have been deposited to GEO under the superseries GSE99748.
Statistical analyses
Data were presented as mean § standard error of the mean (SEM) and analysed by ANOVA with Bonferroni multiple comparisons test for posthoc comparisons or by Student's t-test. No statistical methods were used to predetermine the sample size. Statistical significance of categorical values between groups was designated p < 0.05.
Results
MEF2Cg repressor variant is increased in human and mouse HF
To gain insight into the relevance of MEF2C in the pathophysiology of HF we sought to examine the expression of the transcripts of the MEF2C and the splicing variant domains a, b and g ( Fig. 1a ), in healthy versus failing human hearts. We used samples of commercially available total RNA derived from healthy human left ventricles (n = 5) as controls and biopsy samples of non-infarcted remote zone obtained from the left ventricle of patients (n = 14) with chronic ischemic cardiomyopathy. Clinical and cardiac magnetic resonance imaging (MRI) characteristics of the study group are reported in Supplementary Table 2 . The abundance of full-length MEF2C was increased in most samples of failing hearts (Fig. 1b ). Neither the a1 nor the a2 domain-containing MEF2C transcripts were altered in the RNA samples of failing as compared to those of healthy hearts ( Supplementary Figure 1aÀc ). The b domain was detected neither in the healthy nor in the failing hearts. Notably, however, the expression of MEF2C transcripts containing the g fragment (g+) was significantly increased, while those lacking the g fragment (g-) were decreased in samples of failing as compared to those of healthy human hearts, resulting in a substantial increase of the g+/gÀ ratio in the failing hearts ( Fig. 1c and d) . Therefore, we conclude that there is an increased expression of MEF2C in failing human hearts, which relies on the enhanced expression of the variants containing the g fragment.
Next, we examined the content of the transcripts of the full-length MEF2C and the a, b and g domains in the remote zone of the left ventricle from infarcted and sham-operated mice. The abundance of fulllength MEF2C was increased in most samples of failing hearts (Fig. 1e ). The transcripts containing the a1 and a2 domains were similarly expressed ( Supplementary Figure 1dÀf ), while the transcripts containing the b domain were not detected in samples of the healthy or failing mouse hearts. Consistent with the data obtained in the failing human hearts, the content of the g+ fragment was significantly increased in the hearts from infarcted as compared to those of shamoperated mice ( Fig. 1f and g).
We also examined the expression of the a, b and g domains of MEF2C by RT-PCR in different mouse tissues (heart, brain, skeletal muscle, liver and lung). We observed abundant expression of MEF2C in the brain followed by the heart and the skeletal muscle, with negligible expression in the liver and the lung (Fig. 1h ). The transcripts containing a1 domain expressed predominantly in the brain and the heart, while the transcripts containing a2 domain predominates in the skeletal muscle. The b domain was expressed in the brain tissue, with negligible expression in other tissues. The transcripts containing the g fragment were preferentially detected in the brain, skeletal muscle and heart, respectively, but the predominance in these tissues was of transcripts lacking the g fragment. Overall, our present observations cast MEF2C g+/gÀ ratio, as a potential marker of failing heart, prompting us to investigate the effects of overexpression of the MEF2gand the MEF2g+ isoforms in cardiomyocytes.
MEF2Cg+ overexpression promotes sarcomeric disassembly and apoptosis in cardiomyocytes
We transduced NRVMs with adenoviral expression vectors to address the effects of MEF2Cg+, MEF2CgÀ and the MEF2Cg+23/24 (K23T/R24L) a transcriptionally inactive mutant resulting from loss or diminished DNA binding, on the phenotype and survival of cardiomyocytes. The transductions of the expression vectors were all efficient, as indicated by the comparable expression levels of each type of MEF2C transcript in the NRVMs (Fig. 2a ). The expression levels of the transcripts containing the g fragment in cardiomyocytes transduced with similar amounts of the MEF2Cg+, MEF2CgÀ and MEF2Cg +23/24 adenoviral vectors are shown in Fig. 2b .
The expression of the recombinant MEF2Cg+ (48 h) caused striking morphological changes in the NRVMs. Confocal microscopy observation showed pronounced depletion and disarray of sarcomeres in the perinuclear area ( Fig. 2c) . Also, we observed an increased number of large and bizarre shape nuclei of cardiomyocytes overexpressing MEF2Cg+ ( Fig. 2c and Supplementary Figure 2b) . Notably, no significant morphological change was found in the cardiomyocytes overexpressing MEF2CgÀ or MEF2Cg+23/24 ( Supplementary Figure 2c) . At the ultrastructural level, cells overexpressing MEF2Cg+ showed extensive sarcomeric disassembly and areas containing remnants of the sarcomeres such as clumped Z-band material (Fig. 2d ). No such alterations were seen in NRVMs overexpressing MEF2CgÀ or the inactive MEF2Cg+23/24 ( Supplementary Figure 2d ).
We used TUNEL imaging assay to determine whether the overexpression of MEF2Cg+, MEF2CgÀ or MEF2Cg+23/24 might affect NRVMs viability. We found an increase in the number of TUNEL-positive NRVMs (2-fold) after the transduction with the MEF2Cg+ vector, as compared to the cells transduced with MEF2CgÀ or MEF2Cg+23/24 vectors (Supplementary Figure 3a and b). To further explore the impact of the MEF2Cg + in NRVMs viability, we extended the observation period to five days after the transduction with the viral vector. Distinct from the control cells, most of the cardiomyocytes transduced with MEF2Cg+ showed morphological features of apoptosis ( Supplementary Figure 3c) .
Because there may be differences in the responses between cardiomyocytes derived from neonatal and adult rat hearts to the overexpression of MEF2Cg+, we next examined if the results observed in the NRVMs could be reproduced in cardiomyocytes isolated from adult rats (ARVMs). We used ARVMs cultured for 48 h after the transduction with adenoviral vectors MEF2Cg+, MEF2CgÀ or MEF2Cg+23/24. The efficiency of the transductions in the ARVMs was equivalent among the adenoviral vectors ( Fig. 2e ). The transcripts containing the g fragment increased in the cells transduced with the MEF2Cg+ vector and in those transduced with the MEF2Cg+23/24 vector (Fig. 2f ). The morphology of the ARVMs at 48 h after the transduction with the viral vectors showed control cardiomyocytes with the characteristic rod shape and preserved sarcomeric structure (Fig. 2g) . In contrast, the majority of the ARVMs transduced with the MEF2Cg+ vector lost their rod shape and showed disorganization of the sarcomeric structure (Fig. 2g) . The sarcoplasm of the ARVMs transduced with the MEF2Cg+ vector spread all over the culture dish surface, filled with phalloidin positive material, likely Actin stress fibre; remnants of the sarcomeric structure of the myofibrils were still present at the centre of the cells. Despite the lack of changes in the number of nuclei, we did see consistent increases in the nuclear area of the ARVMs transduced with MEF2Cg+ vector (Supplementary Figure 3d ). ARVMs transduced with MEF2CgÀ, or MEF2Cg +23/24 vectors were morphologically similar to the control cells ( Supplementary Figure 3e) . At the ultrastructural level, ARVMs transduced with the MEF2Cg+ vector showed depletion of sarcomeric structure, particularly in the cell periphery ( Fig. 2h ). No significant change was observed at the ultrastructural level in the ARVMs transduced with MEF2CgÀ, or MEF2Cg+23/24 vectors, as compared to control cells ( Supplementary Figure 3f) . These are the first data to characterize the cardiomyocyte alterations induced by MEF2Cg+ and reveal that this repressor variant of MEF2C may lead to sarcomeric disassembly and changes in the cell nuclei that culminate in cell death.
Transcriptomic differences in cardiomyocytes overexpressing MEF2C variants
Next, we used cDNA microarrays to profile gene expression and compare the relative abundance of gene transcripts in the NRVMs overexpressing the MEF2C variants (MEF2Cg+, MEF2CgÀ or MEF2Cg+23/24) as compared to control cells. We used total RNA extracted from cells 48 h after the viral vector transduction. Statistical analysis was performed with the aim of identifying genes that were differentially expressed between the groups, by a criterion of at least a 2.0-fold change and an adjusted value of P < 0.05 (Deposit number GSE99748, GEO database). Overexpression of MEF2Cg+ resulted in a significant difference in NRVMs transcripts, with 1250 transcripts differentially expressed (676 upregulated and 574 downregulated) out of a total of 28,827, relative to control cardiomyocytes ( Supplementary Figure 4a and d) . Remarkably, neither MEF2CgÀ nor MEF2Cg+23/24 induced substantial changes in gene expression as compared to control cardiomyocytes ( Supplementary  Figure 4b and c ; e and f). As expected, Mef2c transcripts were enriched in NRVMs transduced with MEF2Cg+, MEF2CgÀ or MEF2Cg+23/24 vectors ( Supplementary Figure 4aÀc) . At an initial analysis, we paid particular attention to genes that are known to be targets of MEF2, as annotated in the Ingenuity knowledge-based pathway analysis. Alterations in the expression of the transcripts from 28 MEF2 target genes emerged in the NRVMs overexpressing MEF2Cg+, including genes encoding muscle-specific structural, cytoskeletal, metabolic, stress-responsive proteins and transcription factors ( Supplementary Table 3 ). Notably, all these MEF2 target genes were found to be downregulated in the cardiomyocytes overexpressing MEF2Cg+.
Previous studies have shown that the transrepression function of the gamma domain acts autonomous, i.e., does not involve cis effects on other MEF2 protein functions outside of the domain. However, it remains unclear whether the transrepressor variant interferes in the transactivation function of MEF2 signalling. Here, to test this premise, COS cells were cotransfected with the 3x-MEF2 reporter gene and constructs encoding MEF2A, MEF2D, MEF2Cgand MEF2Cg+. We found that MEF2Cg+ functioned as a dominant-negative form by inhibiting the transcriptional activity of MEF2A, MEF2Cg-and MEF2D ( Supplementary Figure 2a) . These data agree with the repressive effect of the MEF2Cg+ variant on the gene programs under control by MEF2 transcription factors.
Defining MEF2Cg+ -associated pathways
In further analysis, genes differentially expressed in NRVMs transduced with MEF2Cg+ were clustered by function using Gene Ontology (GO) to enrich biological pathways (Fig. 3a) . Supplementary Table 4 provides the complete list and p-values of differentially expressed transcripts and the top associated biological pathways. Transcripts differentially expressed in NRVMs transduced with MEF2Cg+ vector clustered in three main cellular and molecular processes classifications: (i) cell cycle, (ii) energy metabolism, and (iii) cellular component organization. Approximately 10% (124) of the transcripts differentially expressed were annotated as regulators of the cell cycle. A large subset of these transcripts (n = 110) was upregulated in NRVMs transduced with the MEF2Cg+ vector. The top-ranked genes of this subset were selected for confirmation by real-time PCR, including Cyclin E1 (Ccne1), Cyclindependent Kinase 2 (Cdk2) and Aurora Kinase B (Aurkb). Transcripts of all three genes were confirmed to be significantly upregulated in the cardiomyocytes overexpressing MEF2Cg+ (Fig. 3bÀd ). Approximately 29% (365) of the differentially expressed transcripts were classed into the clusters of metabolic processes, of which 182 were reduced in cells transduced with the MEF2Cg+ vector. Several of these genes are predicted to encode proteins related to energy metabolism (Supplementary Table 4 ). Reductions in the transcripts of muscle creatine kinase (Ckm), peroxisome proliferator-activated receptor alpha (Ppara), PPARG coactivator 1 alpha (Ppargc1a) and PPARG coactivator 1 beta (Ppargc1b) were confirmed by RT-PCR (Fig. 3eÀh ). Approximately 3% [35] of the differentially expressed transcripts were classed into the clusters of cellular organization and structure, with a subset downregulated, including sarcomeric genes, such as Sarcomeric a-actinin (Actn2), Cardiac Actin (Actc1), Desmin (Des) and Myosin Heavy Chain isoform a (Myh6) ( Fig. 3iÀl) . Notably, no significant change was observed in the gene expression profile of cardiomyocytes transduced with MEF2CgÀ or MEF2Cg+23/24, as compared to control cardiomyocytes. Several of the genes related to cell cycle, cell metabolism and cellular organization and structure were also changed in adult cardiomyocytes transduced with MEF2Cg+ ( Supplementary Figure 4 gÀo) . These results support a role for MEF2Cg+ in downregulating gene programs related to metabolism, cell organization and structure, but intriguingly, in upregulating markers of cell cycle program in differentiated cardiomyocytes.
MEF2Cg+ stimulates NRVMs cell cycling
Next, we investigated if MEF2Cg+ could change cell cycle activity in cardiomyocytes. Initially, we performed a detailed analysis of the DNA content of NRVMs by propidium iodide flow cytometry. We observed an accumulation of cells in G2/M phase 48 h after the transduction with the MEF2Cg+ expression vector (Fig. 4a) . Transduction with the MEF2Cg+ vector increased the amount of NRVMs in G2/M to 58 § 2%, while transduction with the MEF2CgÀ (22 § 2%) or MEF2Cg +23/24 (21 § 1%) did not change the amount of NRVMs in the G2/M, as compared to controls (22 § 2%), indicating that overexpression of MEF2Cg+ might stimulate cell cycle re-entry in NRVMs.
DNA-synthesis and cell cycle re-entry does not necessarily result in mitosis and cytokinesis in cardiomyocytes. Thus, we performed immunofluorescence staining using an antibody directed to the histone H3 phosphorylated at Ser-10 (pH3), a marker of mitotic activity [19, 20] . Transduction of NRVMs with MEF2Cg+ vector increased the number of pH3 positive cardiomyocytes, by 3-fold, as compared to control and to cells transduced with the MEF2CgÀ, or the MEF2Cg +23/24 vectors (Fig. 4b ). Next, we directly assessed the number of binucleated and multinucleated cardiomyocytes overexpressing MEF2Cg+. Comparisons with NRVMs transduced with MEF2CgÀ, or MEF2Cg+23/24 vectors revealed a MEF2Cg+-dependent increase of binucleated and multinucleated cardiomyocytes by approximately 3-fold ( Supplementary Figure 2b) . These findings indicate that MEF2Cg+ enhances the DNA synthesis in NRVMs but not the progress through cytokinesis.
Repression of cyclin-dependent kinase inhibitors parallel MEF2Cg+ induced cardiomyocyte cycling
We then raised the question as to whether the ability of MEF2Cg+ to determine the cell cycle re-entry in NRVMs might be related to reductions in the abundance of Cyclin-dependent Kinase (CDK) inhibitors, which are critical regulators of cell cycle progression. To date, previous studies have shown that Cdkn1a (P21) is a MEF2-responsive gene [21] . Moreover, our microarray data indicated that the transcripts of Cdkn2b (p15) were reduced in cells transduced with the MEF2Cg+ vector. We then monitored the expression patterns of the transcripts of CDK inhibitors in NRVMs through a period ranging from 12 to 48 h after the transduction with the MEF2Cg+ vector. Cdkn2a (p16) and Cdkn2b (p15) were both significantly reduced in NRVMs throughout the 48 h after the transduction with the MEF2Cg+ vector in comparison to control cells ( Fig. 4c and d) . Cdkn1a (p21) and Cdkn2d (p19) were both significantly reduced in cells 24 h after the transduction with MEF2Cg+ vector, but not after that ( Fig. 4e and f) . Thus, these results suggest that MEF2Cg+ induced cell cycle re-entry in differentiated cardiomyocytes might result from downregulation of cell cycle inhibitors.
MEF2Cg+ but not MEF2CgÀ transgenic mice display dilated cardiomyopathy
Previous work has provided compelling evidence that transgenic MEF2C heart-restricted overexpression leads to dilated cardiomyopathy and heart failure in mice [8] . However, those studies did not clearly define as to which MEF2C variant (MEF2Cg+ or MEF2Cg-) was expressed in the transgenic mice. Here, we performed targeted transgene sequencing and real-time PCR analysis to demonstrate that the MEF2C transgenic mice overexpressed, in fact, MEF2Cg+. Thus, to address the role of the g fragment of MEF2C in the cardiac homostasis, we used the previously published transgenic line that overexpresses the variants a1/bÀ/g+ (TgMEF2Cg+) [8] and produced a new transgenic line, which overexpresses a1/bÀ/gÀ (TgMEF2CgÀ). The MEF2Cg+ and MEF2CgÀ mRNA levels were examined by qPCR, and the transcripts were shown to be increased by 13 and 17 folds, respectively ( Supplementary Figure 5a and b) . Echocardiography analyses indicated a moderate systolic dysfunction of the LV only in the TgMEF2Cg+ ( Supplementary Table 5 ). At necropsy, TgMEF2Cg+ transgenic mice exhibited enlarged ventricular chambers, as compared to TgMEF2CgÀ and control mice (Fig. 5a ). Cardiac histological changes in TgMEF2Cg+ mice included a reduction in the diameter of cardiomyocytes but no significant interstitial fibrosis ( Supplementary Figure 5c  and d) . Electron microscopy analysis of the hearts from the TgMEF2Cg + revealed cardiomyocytes with focal sarcomeric disarrangement (Fig. 5b ). Quantitative analysis showed 14% of fragmented sarcomeres in the TgMEF2Cg+, compared to 0.6% and 1.94% in the WT and TgMEF2CgÀ, respectively (Fig. 5c ). No significant changes were detected in the histological or at the ultrastructural level in the hearts of TgMEF2CgÀ.
Cell cycle, energy metabolism and structural genes are altered in the TgMEF2Cg+ mice
With the evidence of multiple changes in gene expression induced by MEF2Cg+ overexpression in neonatal and adult cardiomyocytes, we were interested in examining if similar changes were present in the failing hearts of TgMEF2Cg+ mice. We performed real-time PCR analysis of representative markers of cell cycle modulators, energy metabolism and cardiomyocyte organization and structure in samples of the hearts of TgMEF2Cg+ and TgMEF2CgÀ mice. As shown in Fig. 5dÀe , there were significant increases in the transcripts of the Ccne1-Cdk2 complex in the LV from the TgMEF2Cg+ mice. By contrast, Ccne1 transcripts were reduced in the hearts of TgMEF2CgÀ as compared to wild-type mice (Fig. 5d ). Moreover, immunohistochemical analysis for the mitosis marker pH3 showed an increased number of pH3-Ser10-positive cardiomyocytes in the hearts of TgMEF2Cg+ mice, indicating an enhanced mitotic entry in the cardiomyocytes of this lineage (Fig. 5fÀg ). Quantitative analysis of TUNEL-positive nuclei of cardiomyocytes revealed an increased number of (3-fold) apoptotic cell death in the TgMEF2Cg+ hearts (Fig. 5hÀi) . These results support the notion that the transgenic expression of MEF2Cg+ in the mouse heart induces cardiomyocyte cell cycle re-entry, without cytokinesis, which culminates in cell death, similarly to the observations in cardiomyocytes in vitro.
The transcripts of genes that were downregulated in NRVMs transduced with MEF2Cg+ vector were similarly changed in the hearts of TgMEF2Cg+ mice. Genes involved in energy metabolism, such as Ckm, Ppargc1a, and Ppara (Fig. 5jÀm ) and cytoskeletal/structural genes such as Myh6 and a-actinin (Actn2) were downregulated in the hearts of the TgMEF2Cg+ mice (Fig. 5nÀo ). However, in contrast to what was found in NRVMs transduced with MEF2Cg-, Ckm, Myh6 and Actn2 were upregulated in MEF2CgÀ transgenic compared to wild-type mice (Fig. 5j, n-o) .
Taken together, the cardiac-specific overexpression of MEF2Cg+ variant induces HF paralleled by partial re-entry in the cell cycle, and downregulation of genes related to energy metabolism and cardiomyocyte structure, which are likely to explain the ensuing structural and functional alterations in the heart of this transgenic mouse model.
Increased cell cycle markers, reduced energy metabolism and cytoskeletal/structural genes in human and mouse failing hearts
Given the enhanced expression of the MEF2Cg+ transcripts in human and in mouse failing hearts, we next explored whether there were derangements in the expression of the cell cycle, energy metabolism and structural marker genes in the human and mouse failing hearts. Cell cycle markers such as Ccne1 and Cdk2 were both increased in failing mouse hearts while CDK2 was increased in failing human hearts (Fig. 6a,b) . Besides, energy metabolism (human À CKM and PPARGC1B and Mouse -Ckm, Ppara, Ppargc1a) ( Fig. 6c,d ) and structural genes (Human À DES and Mouse -Myh6 and Des) were downregulated in the failing hearts ( Fig. 6e,f) . These findings parallel those obtained in isolated NRVMs transduced with the MEF2Cg+ vector and in the failing heart of the TgMEF2Cg+ mice, implying that the enhanced expression of the MEF2Cg+ transcript may be an important factor contributing to the degeneration and death of cardiomyocytes in failing hearts.
Discussion
This study provides evidence for a causal relationship between increased cardiac levels of the transcriptional repressor variant MEF2Cg+ and the development of HF. Our findings in mouse and human heart tissue illustrate an increased expression of MEF2C transcripts containing the transrepressor g fragment in failing hearts.
Mechanistically, our results position the MEF2Cg+ upstream to pathways that regulate the cell cycle, metabolism and contractile apparatus of differentiated cardiomyocytes. Upregulation of MEF2Cg+ causes an incomplete cell cycle re-entry, dedifferentiation and apoptosis of cardiomyocytes which underlie the pathological cardiac remodelling and HF in the MEF2Cg+ transgenic mouse model. Further, our work shows that overexpression of MEF2Cg+ concurs with downregulation of a set of MEF2 target genes, including genes coding for regulators of the cell cycle, cytoskeletal proteins, contractile apparatus and metabolism. These findings suggest that a widespread downregulation of MEF2 target genes may be the initial event that determines an extensive transcriptional reprogramming and the deleterious alterations induced by MEF2Cg+ in cardiomyocytes.
Our results demonstrate that increases of the MEF2Cg+ to the levels seen in murine and human failing hearts are sufficient to cause cardiomyocyte dropout, due to structural disarray and apoptosis. Conceptually, downregulation of genes coding for regulators of energy metabolism, sarcomeric and cytoskeletal proteins, might account for the extensive disarray in cardiomyocyte structural organization and impairment of contractile function, and consequently the development of HF [22À24]. Moreover, our data show that MEF2Cg+ overexpression induces cardiomyocyte apoptosis both in vitro and in vivo, which besides the impairment of contractile activity, is a critical pathogenic event in the progressive cardiac dysfunction and failure [25, 26] . Although many distinct pathways can lead to apoptosis of cardiomyocytes, forcing cardiomyocytes into the cell cycle has been shown in many instances to culminate in apoptosis and lethal HF [27] . More specifically, the incomplete induction of cell cycle can activate the G1/S and G2/M checkpoint signalling in consequence of an accumulation of damaged DNA and failure to complete mitosis, which can lead to cell death [19, 20] . Much evidence has accrued that proteins otherwise associated to the regulation of the cell cycle also participate in mediating cardiomyocyte cell death, including cyclins, cyclin-dependent kinases, CDK inhibitors (p21), Rb Family members, E2Fs and E2F target genes [28] . Consistent with these previous data, our present results show that several genes that drive cell cycle were upregulated in MEF2Cg+ overexpressing cardiomyocytes. However, none of the genes recognized as direct regulators of the cell cycle seem to be targets of MEF2 transcription factors. Instead, MEF2Cg+ overexpression was accompanied by an early downregulation of cell cycle inhibitors such as p15, p16, p19 and p21, suggesting that their direct or indirect inhibition by MEF2Cg+ might contribute to induce the cell cycle re-entry in the cardiomyocytes overexpressing MEF2Cg+. Thus, we postulate that MEF2Cg+ promotes loss of cardiomyocyte structural and functional integrity, and ultimately cell death, via direct or indirect deactivation of multiple genes controlled by MEF2 signalling, which results in disassembly of sarcomeric and cytoskeletal organization, profound changes in metabolism and activation of cell cycle associated with a rather extensive transcriptional reprogramming. Furthermore, it is worth noting that the alterations induced by MEF2Cg+ are akin to partial dedifferentiation of cardiomyocytes, which also recapitulates several phenotypic features seen in cardiomyocytes during pathologic remodelling [29, 30] .
Inclusion of the alternative g domain provides for MEF2C repressor isoforms that carry a phosphoserine-dependent transrepressor function [14] . Despite this potentially important implication in MEF2C biology, to our knowledge, the role of the alternative g fragment in the MEF2C function has not been illustrated before. Our findings that MEF2Cg+ overexpression results in gene deactivation of many MEF2 target genes of cardiomyocytes are in line with the repressive function of this variant of MEF2C. This repressive effect might be related to a direct interaction of such a variant with the specific MEF2 sites in the regulatory regions of MEF2 target genes, implying a role for the recognition of cis-regulatory regions by the MADSbox/MEF2 DNA binding domain of MEF2Cg+ in the repression of MEF2-target genes. However, as the transrepressor function of the g fragment seem to be autonomous [14] , the effects of g fragment are likely to involve the recruitment and physical interaction with transcriptional co-repressors. Besides, data from the present study indicate that the MEF2Cg+ may work as a dominant-negative abrogating the transactivation activity of MEF2A, MEF2C and MEF2D, an effect that might also contribute to the detrimental effects of MEF2Cg+ in cardiomyocytes. In support to this view, previous studies have shown that inhibition of MEF2A or MEF2D in cardiomyocytes results in cellcycle reentry followed by programmed cell death with a significant reduction in sarcomeric genes and upregulation of cell cycle-related genes [31, 32] . Alternatively, as MEF2 by itself is a major regulator of its own promoter activation [33] , one might speculate that the MEF2Cg+ would cause widespread downregulation of gene expression by reducing the expression of the transactivator variants of MEF2C gene. Arguing against this hypothesis, however, are findings that in cardiomyocytes overexpressing MEF2Cg+ there were no major changes in the expression of MEF2 transcripts.
Here, the sarcomeric genes Ckm, Myh6 and Actn2 were downregulated in TgMEF2Cg+ but upregulated in TgMEF2Cg-mice. These antagonistic effects could be explained by the fact that these genes are transcriptionally regulated by MEF2 factors [34À37]. Consequently, cardiomyocytes overexpressing the g repressor domain display downregulation of sarcomeric genes and sarcomeric disassembly. Accordingly, previous studies showed that the transcription inhibition of MEF2C by lysine methyltransferase G9a induces downregulation of sarcomeric-related genes and sarcomeric disassembly in muscle cells [38] .
An important aspect uncovered by our study is that MEF2Cg+ variant is increased to a level that can induce cardiomyocyte detrimental effects in the human and mouse failing hearts, implying that this transrepressor variant of MEF2C may play a role in the pathogenesis of HF in general. Based on this, we propose that MEF2C pre-mRNA could be a downstream target of abnormally activated intracellular signalling mechanisms, leading to a preferential synthesis of MEF2Cg + variant via the contribution of transacting splicing factors. Several splicing factors have been implicated in the regulation of cardiac function and the regulation of the expression of MEF2 variants. For instance, RBFOX1 is a key transacting RNA splicing regulator in cardiomyocytes during HF [16] . Mechanistically, RBFOX1 has global effects on cardiac mRNA splicing in cardiomyocytes and directly regulates isoform switch from a1 to a2 in splicing variants of the MEF2 family.
Interestingly, RBFOX1-mediated MEF2 splicing seems to contribute to cardiomyocyte pathological gene induction. Most remarkably, however, cardiac-specific re-expression of RBFOX1 could significantly attenuate HF in mice. Moreover, other factors such as heterogeneous nuclear ribonucleoprotein U (hnRNP U) and RBM20 are also implicated in the regulation of splicing in cardiomyocytes [39, 40] and might be involved in both, the regulation of MEF2 splicing variants and pathogenesis of heart failure.
In summary, we have demonstrated that enhanced expression of the transrepressor MEF2Cg+ to levels seen in patients with advanced heart failure may induce detrimental alterations in cardiomyocytes and consequently in cardiac pump function. Therefore, the results of this study position the MEF2Cg+ and the mechanisms that control its expression in the failing heart as potential targets for pharmacological strategies aimed at protecting the heart from progressing into failure.
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